All In Biotech

Drug Trial Radar · NCT00005775

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

Randomized Controlled Trial of Parenteral Glutamine Supplementation for Extremely-Low-Birth-Weight (ELBW) Infants

Last checked: Nov 19, 2026Latest source record: Jun 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,433 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,433

Actual

Start

Jul 1999

Primary completion

Dec 2000

Study completion Aug 2001

Sponsor

Lead sponsor
NICHD Neonatal Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Center for Research Resources (NCRR)
First posted
Jun 2, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 72 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This large multicenter double-masked clinical trial tested whether supplementation of standard neonatal parenteral nutrition with glutamine would reduce the risk of death or late-onset sepsis in extremely-low-birth-weight (ELBW, less than or equal to 1000 gm) infants. Neonates with birth weights of 401-1000gm were randomized to standard TrophAmine or TrophAmine supplemented with glutamine before 72 hours and continued until the infants are tolerating full enteral feedings.

Conditions

  • Infant, Newborn
  • Infant, Low Birth Weight
  • Infant, Small for Gestational Age
  • Infant, Premature
  • Sepsis

Interventions

  • GlutamineDrug

    Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.

  • PlaceboDrug

    TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death or late-onset sepsisTime frame: At hospital discharge

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Stanford University

    Palo Alto, California

  • University of California at San Diego

    San Diego, California

  • Yale University

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • Wayne State University

    Detroit, Michigan

  • University of New Mexico

    Albuquerque, New Mexico

  • RTI International

    Durham, North Carolina

  • Cincinnati Children's Medical Center

    Cincinnati, Ohio

  • Case Western Reserve University, Rainbow Babies and Children's Hospital

    Cleveland, Ohio

  • Brown University, Women & Infants Hospital of Rhode Island

    Providence, Rhode Island

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.